TL-938 / Teligene - LARVOL DELTA

TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer (clinicaltrials.gov) - P2 | N=80 | Recruiting | Sponsor: Suzhou Teligene Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Colorectal Cancer • Oncology • Solid Tumor • HER-2 • MSI • RAS

TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer (clinicaltrials.gov) - P2 | N=80 | Not yet recruiting | Sponsor: Suzhou Teligene Ltd. | Initiation date: Dec 2024 ➔ Jul 2025

Trial initiation date • Colorectal Cancer • Oncology • Solid Tumor

A Phase 1 study Evaluating the Safety, Efficacy and Pharmacokinetics of TL938 in HER2-Positive Patients with Advance Solid Tumors. (SABCS 2024) - "TL938 has demonstrated preliminary efficacy as a single agent therapy in HER2+ metastatic breast cancer patients with good tolerance. The most common TRAE observed was diarrhea, which is consistent with other similar tyrosine kinase inhibitors."

Clinical • P1 data • PK/PD data • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2